Glioblastoma Gene-Edited Cell Lines for Drug Discovery

Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumor in adults, classified as a grade 4 astrocytoma by the World Health Organization (WHO). According to the WHO 2021 classification, GBM is defined by IDH-wildtype status. The global age-standardized incidence rate is approximately 3-4 per 100,000 person-years, with a median age at diagnosis of 64 years. The National Cancer Institute (NCI) reports a 5-year relative survival rate of only 6.9% for GBM patients, with a median survival of 12-15 months despite standard therapy (surgical resection, radiotherapy, and temozolomide). Key risk factors include older age, male sex, and exposure to ionizing radiation; no hereditary syndromes account for the majority of cases.

GBM is an ideal model for mechanistic studies due to its well-characterized molecular subtypes (proneural, classical, mesenchymal) defined by The Cancer Genome Atlas (TCGA). The disease exhibits extensive intratumoral heterogeneity, making it a paradigm for studying clonal evolution and therapy resistance. Public datasets from TCGA, cBioPortal, and the Gene Expression Omnibus (GEO) provide rich multi-omics data (DNA methylation, RNA-seq, copy number alterations) for hypothesis generation. Open questions include the role of glioma stem cells (GSCs), the tumor microenvironment, and mechanisms of resistance to targeted therapies and immunotherapies.

GBM pathogenesis involves several key pathways:

• • RTK/RAS/PI3K pathway: Receptor tyrosine kinase (RTK) amplification (e.g., EGFR, PDGFRA) activates RAS and PI3K/AKT signaling, promoting cell proliferation and survival.

1. RTK activation (e.g., EGFR amplification or EGFRvIII mutation).

2. PI3K activation via PIK3CA mutation or PTEN loss.

3. AKT phosphorylation leading to mTOR activation.

• • TP53 pathway: TP53 mutations (found in ~30% of GBM) disrupt cell cycle arrest and apoptosis, often co-occurring with MDM2 amplification or CDKN2A deletion.
• • RB pathway: CDKN2A deletion (in ~50% of GBM) leads to loss of p16INK4a, allowing CDK4/6 to phosphorylate RB and drive cell cycle progression.
• • Wnt/β-catenin pathway: Aberrant activation contributes to stemness and invasion, though less frequent than in other cancers.

Data from TCGA (Cancer Genome Atlas Research Network, 2008) and COSMIC (v99):

Key deregulated networks in GBM:

• • PI3K/AKT/mTOR: Central node integrating RTK signals; PTEN loss is a hallmark. Key nodes: AKT, mTORC1, S6K, 4E-BP1.
• • MAPK/ERK: RAS-RAF-MEK-ERK cascade; activated by EGFR, PDGFRA, and NF1 loss. Key nodes: KRAS, BRAF, MEK1/2, ERK1/2.
• • p53/MDM2: TP53 mutations disrupt DNA damage response; MDM2 amplification (10%) further inhibits p53. Key nodes: TP53, MDM2, CDKN2A.
• • RB/E2F: CDKN2A deletion releases E2F transcription factors, driving S-phase entry. Key nodes: RB1, CDK4/6, cyclin D1.
• • Notch: Involved in stem cell maintenance and angiogenesis; activated in GSCs. Key nodes: NOTCH1, DLL1, JAG1.

Commonly used GBM cell lines and their key mutations:

Organoids offer advantages over 2D cultures by preserving 3D architecture, cell-cell interactions, and hypoxic gradients, making them more physiologically relevant for studying invasion and drug response.

Common in vivo models for GBM:

• • Patient-derived xenografts (PDX): Implantation of patient tumor cells into immunodeficient mice (e.g., NSG). Retains tumor heterogeneity and molecular features.
• • Example: U87MG xenografts in flank or orthotopic brain.
• • Genetically engineered mouse models (GEMM): Conditional knock-in of GBM drivers (e.g., EGFRvIII, PDGFRA) with TP53 deletion.
• • Example: GFAP-Cre; Trp53 fl/fl; Pten fl/fl model.
• • Induced models: Viral delivery of oncogenes (e.g., RCAS/tv-a system) to express PDGFB or KRAS in glial cells.
• • Example: RCAS-PDGFB injection into neonatal mice.

CRISPR/Cas9 gene editing enables the creation of isogenic cell lines with precise genetic modifications, allowing researchers to study the functional impact of specific GBM mutations in a controlled background. Examples include:

• • TP53 knockout: In U87MG or LN229 cells, generating TP53-null lines to study loss of tumor suppression.
• • PTEN knockout: In U87MG cells (which have wild-type PTEN), to model PI3K pathway activation.
• • EGFRvIII knock-in: In U87MG or U251MG cells, introducing the constitutively active EGFR variant to study RTK signaling.
• • IDH1 R132H knock-in: In U87MG or patient-derived lines, to model the neomorphic IDH mutation in secondary GBM.

Commercially available, sequence-verified gene-edited cell models accelerate research by eliminating the need for in-house editing validation, ensuring reproducibility. These models are used for target validation, drug screening, and functional genomics studies. Note: No specific company names are mentioned; models are available from commercial sources.

Gene-edited cells are essential for validating the functional role of GBM-associated genes. For example:

• • TP53 knockout in U87MG cells confirms its role in cell cycle arrest and apoptosis; TP53-null cells show increased proliferation and resistance to DNA-damaging agents.
• • PTEN knockout in LN229 cells demonstrates enhanced AKT phosphorylation and invasive capacity.
• • EGFRvIII knock-in in U251MG cells reveals downstream MAPK activation and increased tumor growth in xenografts.
• • IDH1 R132H knock-in in U87MG cells recapitulates the 2-hydroxyglutarate production and DNA hypermethylation phenotype.

Isogenic cell pairs (e.g., wild-type vs. TP53 knockout) are powerful tools for drug screening:

• • Isogenic pair screens: Compare drug sensitivity between mutant and wild-type cells to identify genotype-specific vulnerabilities. For example, PTEN-null cells may show increased sensitivity to PI3K inhibitors.
• • Resistance modeling: Chronic exposure of gene-edited cells to drugs (e.g., temozolomide) can select for resistance mutations. CRISPR knock-in of resistance alleles (e.g., MGMT overexpression) validates mechanisms.
• • Combination therapy testing: Gene-edited cells allow testing of targeted agents (e.g., EGFR inhibitors) in the context of specific mutations.

CRISPR-based synthetic lethality screens in GBM cell lines identify novel therapeutic targets:

• • Synthetic lethality: For example, in PTEN-null cells, screening for genes whose knockout is lethal identifies vulnerabilities like CHK1 or ATR.
• • CRISPR knockout libraries: Genome-wide screens in isogenic lines (e.g., TP53 wild-type vs. mutant) reveal context-specific dependencies.
• • Biomarker validation: Gene-edited models confirm that expression of a target (e.g., EGFRvIII) correlates with drug response, supporting its use as a predictive biomarker.